InvestSMART

Imagion Biosystems Limited (ASX: IBX) - Share Price

- Current share price for IBX : $0.005

Imagion Biosystems (IBX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense, a MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision.

IBX General Information +

ASX Code IBX
Website http://imagionbiosystems.com
Industry/Sector Health Care Equipment
Market Cap ($M) 4
IBX Share Price $0.005
Day High $0.006
Day Low $0.005
Last Close $0.005
IBX Share Price Movement - ( No change )
Prices as at 16:35, 30 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Imagion Biosystems Limited (IBX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Imagion Biosystems Limited (IBX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Imagion Biosystems Limited (IBX) price-sensitive announcements

IBX - Appendix 4C and Quarterly Activities Report - September 2026
Imagion Biosystems Limited (ASX: IBX) reported in its Quarterly Activities Report and Appe
Imagion Biosystems Limited (IBX)
8 Oct 2026 | 9:19 AM
IBX - IBX Secures Central Ethics Approval - Key Phase 2 Milestone
Imagion Biosystems Limited (ASX: IBX) announced that Advarra, Inc. has granted central Ins
Imagion Biosystems Limited (IBX)
30 Sep 2026 | 9:57 AM
IBX - MagSense Nanoparticle Manufacturing Update
Imagion Biosystems Limited (ASX: IBX) announced that it has resumed MagSense® nanoparticle
Imagion Biosystems Limited (IBX)
14 Sep 2026 | 9:03 AM
IBX - IBX Phase 2 Clinical Trial Update
Imagion Biosystems Limited has provided an update on its Phase 2 clinical trial involving
Imagion Biosystems Limited (IBX)
26 Aug 2026 | 9:47 AM

Imagion Biosystems Limited (IBX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 IBX Announces NED Resignation & Change of Company Secretary 30 Oct 2026 2:19PM $0.006 $0.005 fallen by 9.09%
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 Amended Appendix 4C - September 2026 26 Oct 2026 6:36PM $0.005 $0.005 fallen by 0%
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 Appendix 4C and Quarterly Activities Report - September 2026 8 Oct 2026 9:19AM $0.006 $0.005 fallen by 16.67%
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 IBX Secures Central Ethics Approval - Key Phase 2 Milestone 30 Sep 2026 9:57AM $0.008 $0.005 fallen by 33.33%
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 MagSense Nanoparticle Manufacturing Update 14 Sep 2026 9:03AM $0.008 $0.005 fallen by 37.50%
Imagion Biosystems Limited (IBX)
ORDINARY FULLY PAID
Health Care $4 IBX Investor Presentation 4 Sep 2026 9:26AM $0.008 $0.005 fallen by 37.50%

IBX Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$4.31 -$1.60 -77.30% 0.00 0.00 0.00% 0.0%
2024A -$3.08 -$6.80 -84.00% 0.00 0.00 0.00% 0.0%
2023A -$13.07 -$42.90 22.50% 0.00 0.00 0.00% 0.0%

IBX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Cochlear Limited (COH) $9,156M -0.3136 0.2540 0.0785 34.0840 27.1802 25.2021 2.46% 2.56% 2.79%
Fisher & Paykel Healthcare Corporation Limited (FPH) $22,248M 0.1388 0.1452 0.1573 57.1904 49.9406 43.1538 1.15% 1.24% 1.38%
Imagion Biosystems Limited (IBX) $4M -0.7734 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Imricor Medical Systems Inc (IMR) $481M -0.4254 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ResMed Inc. (RMD) $20,029M 9.5922 0.1012 0.0991 22.8102 20.7147 18.8476 1.02% 1.11% 1.20%

IBX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -1.14 0.00
Market 0.30 13.20 1.03 0.74
Sector 0.72 21.80 1.76 2.45

IBX Directors

Name Position Start Date
Ms Melanie Jaye Leydin Company Secretary, Non-Execufive Director 1 Aug 2024
Mr Robert Romeo Proulx Executive Director, Executive Chairman 6 Dec 2016
Mr Brett Anthony Mitchell Non-Executive Director 14 Jun 2024
Dr Nina Webster Non-Executive Director 1 Sep 2025

Imagion Biosystems Limited (IBX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
18 Aug 2026 WEBSTER, Nina Issued Indirect Shares 2,083,334 $0.012 $25,000.000
18 Aug 2026 MITCHELL, Brett Issued Indirect Shares 2,083,334 $0.012 $25,000.008
18 Aug 2026 PROULX, Robert Issued Direct Shares 2,083,334 $0.012 $25,000.000

See all changes in directors' interest & trades for Imagion Biosystems Limited (IBX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IBX Calendar of Events

Date Event
23 August 2027 Report (Interim)
26 February 2027 Report (Annual)
26 February 2027 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.